Meta-analysis of medical and non-medical treatments of the prodromal phase of psychotic illness in at-risk mental states.

INTRODUCTION there are now many existing studies which assess the treatments available for 'at risk mental states', as patients who are believed to be in the prodromal phase of psychotic illness are referred to. However, concerns regarding side effects of possible treatments remain. We here conduct a meta-analysis of the studies available up to October 2010. The aim of this study is to decide what would be the best treatment for 'at high risk patients'. RESULTS all the available studies examining potential treatments during the prodromal phase of psychotic illness were collected. They all showed comparable efficacy, which reached statistical significance, excluding the one study using olanzapine, which in fact 'tended towards significance'. DISCUSSION treatments appear promising but a balance needs to be kept between adverse events and effectiveness of preventing psychosis. CONCLUSION it is necessary to search further for treatments in order to identify effective treatments with fewer adverse side effects in this phase of psychotic illness.

[1]  A. Mackinnon,et al.  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. , 2010, Archives of general psychiatry.

[2]  R. Zaman,et al.  The ethics of identifying and treating psychosis early. , 2008, Psychiatria Danubina.

[3]  W. Gaebel,et al.  Acute effects of treatment for prodromal Acute effects of treatment for prodromal symptoms for people putatively in a late initial symptoms for people putatively in a late initial , 2007 .

[4]  Shuki J. Cohen,et al.  Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. , 2007, The British journal of psychiatry. Supplement.

[5]  M. Berk,et al.  Neuroprotection in emerging psychotic disorders , 2007 .

[6]  C. Correll,et al.  Can antidepressants be used to treat the schizophrenia prodrome? Results of a prospective, naturalistic treatment study of adolescents. , 2007, The Journal of clinical psychiatry.

[7]  W. Maier,et al.  Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment , 2007, Early intervention in psychiatry.

[8]  Adrian Preda,et al.  Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. , 2006, The American journal of psychiatry.

[9]  G. Krarup,et al.  Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment , 2006, Schizophrenia Research.

[10]  R. Bentall,et al.  Cognitive therapy for the prevention of psychosis in people at ultra-high risk , 2004, British Journal of Psychiatry.

[11]  Hok Pan Yuen,et al.  Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. , 2002, Archives of general psychiatry.

[12]  R. Bentall,et al.  Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals , 2002, British Journal of Psychiatry.

[13]  R. Bentall,et al.  More harm than good: The case against using antipsychotic drugs to prevent severe mental illness , 2002 .

[14]  A. Mackinnon,et al.  Long-Chain -3 Fatty Acids for Indicated Prevention of Psychotic Disorders A Randomized, Placebo-Controlled Trial , 2010 .

[15]  C. Correll,et al.  The schizophrenia prodrome revisited: a neurodevelopmental perspective. , 2003, Schizophrenia bulletin.